BioSpace News Archive

VectivBio Holding AG today reported financial results and provided a business update for the full year ended December 31, 2021.

Pathalys Pharma, Inc. today announced plans for a phase 3 program to support the application of upacicalcet (designated PLS240 for clinical trials), globally.

Agile Therapeutics, Inc. will be presented at the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting.

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 3rd, 2022.

Propella Therapeutics, Inc. (“Propella”), and Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm), today announced that the companies have entered into an exclusive licensing agreement for CGS-200-5, a clinical-stage topical treatment that is being developed for the treatment of pain in patients with moderate to severe osteoarthritis (OA) of the knee.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive efficacy results from the Phase 1b segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (“AD”).

Sequence Bio announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio’s proprietary discovery platform to identify novel dermatologic drug targets.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 20 new employees.

McKesson Corporation announced that it has closed the transaction announced in November 2021 to sell its UK businesses to AURELIUS.

Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2022 financial results on Thursday, April 28, 2022 after the close of U.S. financial markets.